Benchmark Holdings (BMK) AI Stock Analysis

• Market Cap: £151.27M
• Dividend Yield: N/A
• Average Volume (3M): 292.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -16.14%
• EPS Growth: -68.06%
• Country: UK
• Employees: 800
• Sector: Healthcare
• Sector Strength: 71
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.04
• Shares Outstanding: 741,505,700
• 10 Day Avg. Volume: 356,208
• 30 Day Avg. Volume: 292,672
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.13
• Price to Cash Flow (P/CF): 24.30
• P/FCF Ratio: 11.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Benchmark Holdings is facing significant financial difficulties, with declining revenue and net losses affecting its financial health. The stock's technical indicators suggest a bearish trend, and the valuation is unattractive due to negative earnings. However, the proactive debt management through early bond redemption is a positive development but not enough to offset the overall negative outlook.

Benchmark Holdings Business Overview & Revenue Model

Company Description

Benchmark Holdings (BMK) is an aquaculture biotechnology company focused on improving the sustainability and efficiency of aquaculture. The company operates in sectors such as genetics, advanced nutrition, and animal health, offering a range of products and services designed to enhance fish farming practices. Key offerings include breeding programs, specialized feeds, and health products that target disease management in aquaculture species.

How the Company Makes Money

Benchmark Holdings generates revenue through the sale of its genetics, advanced nutrition, and animal health products. The genetics segment earns income by providing breeding and genetic improvement services, which help aquaculture producers improve the quality and yield of their stock. The advanced nutrition segment contributes to revenue through the sale of specialized feeds and dietary supplements that promote growth and health in farmed fish. The animal health segment derives income from selling disease management solutions, including vaccines and treatments. Significant partnerships with aquaculture producers and research institutions, as well as ongoing innovation and product development, also play a vital role in supporting and expanding the company's revenue streams.

Benchmark Holdings Financial Statement Overview

Summary

Benchmark Holdings faces financial challenges with declining revenues, persistent net losses, and cash flow issues. While the balance sheet shows some stability, ongoing negative cash flows and profitability issues indicate a need for strategic adjustments to ensure financial health and growth potential.

Income Statement

Benchmark Holdings has faced declining revenue with a 25% decrease in the most recent TTM. The company struggles with profitability as evidenced by negative EBIT and net income margins. Despite positive EBITDA margins, the overall financial health of the income statement is weak due to consistent net losses.

Balance Sheet

The balance sheet shows moderate stability with a debt-to-equity ratio of approximately 0.35, indicating manageable leverage. However, the equity ratio has decreased, reflecting reduced asset efficiency. The company's equity position has weakened over the years, needing attention to sustain long-term stability.

Cash Flow

The cash flow statement reveals negative free cash flow growth, driven by declining operating cash flow and increased capital expenditures. The company struggles to convert net income into cash, highlighted by negative operating and free cash flow to net income ratios. This highlights potential liquidity concerns.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
67.61M	90.36M	169.48M	158.28M	125.06M	105.56M
	Gross Profit
25.62M	43.95M	86.75M	83.13M	65.58M	54.96M
	EBIT
-35.89M	-35.50M	-5.32M	-4.76M	-1.01M	-7.68M
	EBITDA
5.78M	10.97M	34.20M	28.35M	24.36M	14.34M
	Net Income Common Stockholders
-41.76M	-39.46M	-23.15M	-30.45M	-11.58M	-22.77M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.81M	23.09M	36.52M	36.40M	39.46M	71.61M
	Total Assets
380.77M	384.90M	471.30M	526.57M	481.99M	489.04M
	Total Debt
75.84M	72.07M	102.00M	110.14M	120.39M	109.16M
	Net Debt
62.03M	48.98M	65.47M	73.74M	80.93M	37.55M
	Total Liabilities
155.33M	160.63M	188.68M	203.29M	202.39M	193.59M
	Stockholders Equity
219.74M	218.26M	276.40M	313.40M	271.71M	289.13M
Cash Flow		Free Cash Flow
-6.50M	-1.92M	13.22M	-1.91M	-16.93M	-15.47M
	Operating Cash Flow
-2.72M	2.00M	20.00M	10.81M	5.79M	-4.06M
	Investing Cash Flow
-2.81M	-2.83M	-5.27M	-11.22M	-23.09M	30.38M
	Financing Cash Flow
-4.05M	-10.97M	-12.33M	-6.92M	-14.67M	30.13M

Benchmark Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BMK, the sentiment is Negative. The current price of 20.5 is below the 20-day moving average (MA) of 23.61, below the 50-day MA of 25.73, and below the 200-day MA of 34.30, indicating a bearish trend. The MACD of -0.78 indicates Positive momentum. The RSI at 27.78 is Positive, neither overbought nor oversold. The STOCH value of 38.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BMK.

Benchmark Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TET	70 Outperform	£131.89M	9.13	10.31%	3.90%	3.85%	31.09%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
AGY	48 Neutral	£271.69M	―	-369.20%	―	4.50%	74.32%
BMK	37 Underperform	£151.27M	―		―	-16.14%	-68.06%

Benchmark Holdings Corporate Events

Benchmark Holdings to Redeem Outstanding Bonds Ahead of Schedule

Benchmark Holdings PLC announced its decision to exercise a call option to redeem all outstanding bonds from its senior unsecured bond issue, originally set to mature in September 2025. This strategic financial move, scheduled for completion by April 15, 2025, is expected to impact the company’s financial structure by addressing its debt obligations earlier than planned, potentially enhancing its market position and stakeholder confidence.

Benchmark Holdings Completes Sale of Genetics Business

Benchmark Holdings has completed the sale of its genetics business to Starfish Bidco, a subsidiary of Novo Holdings, for an enterprise value of £260 million. This transaction is expected to yield gross cash proceeds of approximately £194 million, with net cash proceeds of about £107.5 million after debt repayments. The sale aligns with Benchmark’s strategic focus, and further details on the use of proceeds will be provided in mid-April.

Benchmark Holdings Updates Total Voting Rights

Benchmark Holdings plc announced an update on its total voting rights, reporting an issued share capital of 741,505,672 ordinary shares as of March 31, 2025. This increase in shares, attributed to the routine exercise of options by employees, impacts the calculation for shareholders to notify changes in their interest in the company.

Benchmark Holdings Reports Transitional Q1 FY25 Amid Genetics Business Sale

Benchmark Holdings reported its Q1 FY25 results, highlighting a transitional period as it moves towards completing the sale of its Genetics business and streamlining its operations. The company experienced a 30% decline in revenues from continuing operations compared to the previous year, primarily due to softness in shrimp markets and a change in product mix. Despite these challenges, the Health segment showed resilience, focusing on Salmosan® Vet. Benchmark is progressing with a new joint venture to develop a land-based model for Ectosan® Vet and CleanTreat®. The company plans to use proceeds from the Genetics sale to strengthen its balance sheet and return capital to shareholders.

Benchmark Holdings Updates Total Voting Rights

Benchmark Holdings PLC, a company involved in the field of biotechnology and aquaculture, announced that its total issued share capital now consists of 741,455,200 ordinary shares, all with voting rights, as of 28 February 2025. This increase in shares is attributed to the routine exercise of options by current and former employees, impacting the total voting rights available, which shareholders can use to assess their interest in the company.

Benchmark Holdings Schedules 2025 AGM for March 11

Benchmark Holdings plc has announced the scheduling of its Annual General Meeting (AGM) for March 11, 2025, at DLA Piper’s offices in London. The notice and proxy forms for the AGM are being sent to shareholders and will be available on the company’s website, underscoring Benchmark’s continued commitment to transparency and shareholder engagement.

Benchmark Holdings Updates Total Voting Rights

Benchmark Holdings PLC has announced an update regarding its total voting rights, effective 31 January 2025. The company’s issued share capital now consists of 741,272,980 ordinary shares with voting rights, following a routine exercise of options by current and former employees. This figure will serve as the denominator for shareholders to calculate any changes in their interest in the company.